Dendritic cell-based therapeutic cancer vaccines: what we have and what we need

By Kalinski Pawel   Urban Julie   Narang Rahul   Berk Erik   Wieckowski Ewa   Muthuswamy Ravikumar  

Future Oncology, Vol. 5, Iss. 3, 2009-04 ,pp. : 379-390

Future Medicine

Access to resources Recommend Favorite

FOXM1 is overexpressed in B-acute lymphoblastic leukemia (B-ALL) and its inhibition sensitizes B-ALL cells to chemotherapeutic drugs

By          

International Journal of Oncology, Vol. 47, Iss. 4, 2015-01 ,pp. : 1230-1240

Spandidos Publications

Access to resources Recommend Favorite

New drugs and clinical trial design in advanced sarcoma: have we made any progress?

By Constantinidou Anastasia   Miah Aisha   Pollack Seth   Jones Robin L  

Future Oncology, Vol. 9, Iss. 10, 2013-10 ,pp. : 1409-1411

Future Medicine

Access to resources Recommend Favorite

Parasitic Vaccines—Still Trying After All These Years

By  

The Genesis Report - Rx, Vol. 8, Iss. 6, 1999-10 ,pp. : 8-11

Adis International

Access to resources Recommend Favorite

HPV and Therapeutic Vaccines: Where are We in 2010?

By  

Current Cancer Therapy Reviews, Vol. 6, Iss. 2, 2010-05 ,pp. : 81-103

Bentham Science Publishers

Access to resources Recommend Favorite